Yang Jun, Gong Chaoju, Ke Qinjian, Fang Zejun, Chen Xiaowen, Ye Ming, Xu Xi
Department of Orthopedic Surgery, Sanmen People's Hospital of Zhejiang Province, Sanmenwan Branch of the First Affiliated Hospital, College of Medicine, Zhejiang University, Sanmen, China.
Central Laboratory, The Municipal Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Front Oncol. 2021 Jun 10;11:661620. doi: 10.3389/fonc.2021.661620. eCollection 2021.
Histone deacetylase 5 (HDAC5) is a class II HDAC. Aberrant expression of HDAC5 has been observed in multiple cancer types, and its functions in cell proliferation and invasion, the immune response, and maintenance of stemness have been widely studied. HDAC5 is considered as a reliable therapeutic target for anticancer drugs. In light of recent findings regarding the role of epigenetic reprogramming in tumorigenesis, in this review, we provide an overview of the expression, biological functions, regulatory mechanisms, and clinical significance of HDAC5 in cancer.
组蛋白去乙酰化酶5（HDAC5）是一种II类组蛋白去乙酰化酶。HDAC5在多种癌症类型中均有异常表达，其在细胞增殖与侵袭、免疫反应以及干性维持中的功能已得到广泛研究。HDAC5被认为是抗癌药物的可靠治疗靶点。鉴于近期关于表观遗传重编程在肿瘤发生中作用的研究发现，在本综述中，我们概述了HDAC5在癌症中的表达、生物学功能、调控机制及临床意义。
